Literature DB >> 12017355

Evaluating public commentary and scientific evidence submitted in the development of a risk assessment.

Marieka S Schotland1, Lisa A Bero.   

Abstract

Risk assessments form the methodological basis for many public policies. A key component of the risk assessment process is the public commentary period. We conducted a case study of the California environmental tobacco smoke risk assessment to describe the contribution of the commentary to the risk assessment process. We used content analysis to examine the sources, quantity, and quality of public commentary, as well as the agency's response to the commentary. We examined the type and quality of publications cited in the commentary. Most of the comments were from critics of the risk assessment (36/44, 80%), especially tobacco industry affiliates (30/36, 83%). Critics were more likely to evoke the science evaluation criteria of study quality, reliability, and validity than were supporters. More than half the critics argued that appropriate procedures were not followed (13/23, 57%). Of the 29 commentaries on the respiratory, carcinogenic, and cardiovascular chapters, four resulted in changes to the risk assessment, such as the addition of new references or reanalysis of data. Journal articles were the most frequently cited type of reference, cited by critics (1,022/1,526 of references, 67%) and supporters (39/60, 65%). However, journal articles submitted by critics had lower impact factors than those cited by supporters (2.6 vs. 3.6, p=0.03). Participation in the public input process was not balanced among all interested parties, although this may reflect different opportunities for stakeholders to participate in stages of the process. Critics and supporters of the risk assessment used different criteria to evaluate the scientific evidence, suggesting that they were socially constructing the evidence to support their positions.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12017355     DOI: 10.1111/0272-4332.t01-1-00011

Source DB:  PubMed          Journal:  Risk Anal        ISSN: 0272-4332            Impact factor:   4.000


  8 in total

Review 1.  Review of the quality of studies on the economic effects of smoke-free policies on the hospitality industry.

Authors:  M Scollo; A Lal; A Hyland; S Glantz
Journal:  Tob Control       Date:  2003-03       Impact factor: 7.552

2.  How the tobacco industry responded to an influential study of the health effects of secondhand smoke.

Authors:  Mi-Kyung Hong; Lisa A Bero
Journal:  BMJ       Date:  2002-12-14

Review 3.  Tobacco industry manipulation of research.

Authors:  Lisa A Bero
Journal:  Public Health Rep       Date:  2005 Mar-Apr       Impact factor: 2.792

4.  Tobacco industry efforts to defeat the occupational safety and health administration indoor air quality rule.

Authors:  Katherine Bryan-Jones; Lisa A Bero
Journal:  Am J Public Health       Date:  2003-04       Impact factor: 9.308

5.  The tobacco industry's role in the 16 Cities Study of secondhand tobacco smoke: do the data support the stated conclusions?

Authors:  Richard L Barnes; S Katharine Hammond; Stanton A Glantz
Journal:  Environ Health Perspect       Date:  2006-12       Impact factor: 9.031

Review 6.  Conflicts of interest and critiques of the use of systematic reviews in policymaking: an analysis of opinion articles.

Authors:  Susan R Forsyth; Donna H Odierna; David Krauth; Lisa A Bero
Journal:  Syst Rev       Date:  2014-11-18

7.  Compromise or capitulation? US Food and Drug Administration jurisdiction over tobacco products.

Authors:  Stanton A Glantz; Richard Barnes; Sharon Y Eubanks
Journal:  PLoS Med       Date:  2009-07-28       Impact factor: 11.069

8.  Representation and misrepresentation of scientific evidence in contemporary tobacco regulation: a review of tobacco industry submissions to the UK Government consultation on standardised packaging.

Authors:  Selda Ulucanlar; Gary J Fooks; Jenny L Hatchard; Anna B Gilmore
Journal:  PLoS Med       Date:  2014-03-25       Impact factor: 11.069

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.